Macro Scientific

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics for the treatment of cancer. The company leverages its proprietary suite of next-generation antibody technologies, including the DART (Dual-Affinity Re-Targeting) and TRIDENT platforms, to create multi-specific antibodies that can engage multiple targets simultaneously. Their lead product, Margenza (margetuximab-cmkb), is an Fc-optimized monoclonal antibody approved for the treatment of certain types of metastatic HER2-positive breast cancer. MacroGenics maintains a robust pipeline of candidates targeting various immune checkpoints and tumor antigens, often in collaboration with major pharmaceutical partners. The company's approach emphasizes enhancing the body's immune response to tumors through sophisticated protein engineering.